News tagged with genentech
US panel rejects Avastin for breast cancer use
An expert panel urged the US Food and Drug Administration on Wednesday to strip the Roche-made drug Avastin of its label for use against breast cancer because it is neither safe nor effective.
Medicine & Health / Medications
Jun 29, 2011 |
not rated yet |
0
FDA panel: Revoke drug's breast cancer approval
(AP) -- A panel of cancer experts has ruled for a second time that Avastin, the best-selling cancer drug in the world, should no longer be used in breast cancer patients, clearing the way for the government to remove its ...
Medicine & Health / Medications
Jun 28, 2011 |
not rated yet |
0
Apple names Arthur Levinson non-exec chair
(AP) -- Apple Inc. has named Arthur Levinson as its non-executive chairman, a move that rewards the longtime Apple board member who chose it over Google Inc. when the technology giants began to compete with ...
Nov 15, 2011 |
not rated yet |
1
Analysis details Avastin's rare fatal side effects
(AP) -- A new analysis raises fresh questions about the risks of the blockbuster cancer drug Avastin, suggesting the chance of dying from side effects linked to it is higher than the risk for patients on chemotherapy alone.
Medicine & Health / Medications
Feb 01, 2011 |
not rated yet |
1
FDA warns of heart risk with HIV drug combination
(AP) -- The Food and Drug Administration issued a warning Tuesday about potential heart risks when combining two HIV drugs.
Medicine & Health / Medications
Feb 23, 2010 |
not rated yet |
0
FDA says breast cancer drug did not extend lives
(AP) -- Federal health scientists said Friday that follow-up studies of a Roche breast cancer drug show it failed to slow tumor growth or extend patient lives, opening the door for a potential withdrawal in that indication.
Medicine & Health / Medications
Jul 16, 2010 |
5 / 5 (1) |
1
Justice probing tech company recruiting
The US Justice Department has launched an investigation into whether the recruiting practices of some of the largest US technology companies violated antitrust laws, The Washington Post reported on Wednesday.
Jun 03, 2009 |
not rated yet |
0
Roche to take over Genentech for $47 billion
(AP) -- Swiss pharmaceutical giant Roche said Thursday it has agreed to buy California-based Genentech for $46.8 billion in a takeover described as the largest in Swiss corporate history.
Medicine & Health / Medications
Mar 12, 2009 |
not rated yet |
0
Genentech
Genentech Inc., or Genetic Engineering Technology, Inc., is a biotechnology corporation, founded in 1976 by venture capitalist Robert A. Swanson and biochemist Dr. Herbert Boyer. Trailing the founding of Cetus by five years, it was an important step in the evolution of the biotechnology industry. One of its founders, Boyer, is considered to be a pioneer in the field of recombinant DNA technology. In 1973, Boyer and his colleague Stanley Norman Cohen demonstrated that restriction enzymes could be used as "scissors" to cut DNA fragments of interest from one source, to be ligated into a similarly cut plasmid vector. While Cohen returned to the laboratory in academia, Swanson contacted Boyer to found the company. Boyer worked with Arthur Riggs and Keiichi Itakura from the Beckman Research Institute, and the group became the first to successfully express a human gene in bacteria when they produced the hormone somatostatin in 1977. David Goeddel and Dennis Kleid were then added to the group, and contributed to its success with synthetic human insulin in 1978.
As of February 2011, Genentech employed more than 11,000 people. The Swiss pharmaceutical conglomerate Hoffmann-La Roche now completely owns Genentech after completing its purchase on March 26, 2009 for approximately $46.8 billion.
For more information about Genentech, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
